Phathom Pharmaceuticals Inc
PHAT
Get informed when a big investor buys or sells
+ FollowMarket Cap$691.7M
Close$
$-4.09
144.6% downside
Current Fair Value
144.6% downsideOvervalued by 144.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $691.70 Million |
|---|---|
| Enterprise Value | $511.75 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.03 |
| Beta | 0.49 |
| Outstanding Shares | 83,747,104 |
Return
| Return on Equity | -58.12% |
|---|---|
| Return on Assets | 61.18% |
| Return on Invested Capital | 164.57% |
Valuation & Multiples
| P/E Ratio | -6.68 |
|---|---|
| PEG | 6.68 |
| Price to Sales | 4.59 |
| Price to Book Ratio | -1.84 |
| Enterprise Value to Revenue | 2.14 |
| Enterprise Value to EBIT | 1.79 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$73.45 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$85.42 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 5.77% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 25.99%▼ 68.48% |
|---|---|
| Total Invested | $231.41M▼ 69.77% |
| Investors Holding | 43▼ 136.00% |
ESG Score
No data
About Phathom Pharmaceuticals Inc
55 employeesPhathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, E...